glp1
Exenatide tracker
Educational reference for Exenatide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
2.4 h
Tmax
2.1 h
Category
glp1
Also known as: Byetta, exendin-4
Exenatide is an FDA-approved GLP-1 receptor agonist for type 2 diabetes. Subcutaneous injection.
Mechanism
A GLP-1 receptor agonist derived from exendin-4, a peptide originally identified in Gila monster venom. It resists rapid degradation relative to native GLP-1 and is associated with glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite.
Research summary
One of the earliest approved GLP-1 receptor agonists for type 2 diabetes, available in twice-daily and extended-release once-weekly formulations. Marketed as Byetta and Bydureon.
Reported side effects
Gastrointestinal effects (nausea, vomiting, diarrhea) are most commonly reported. Prescribing information includes warnings such as pancreatitis and, for the extended-release form, thyroid C-cell tumor risk in rodents. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Exenatide clinical development in type 2 diabetes · peer-reviewed clinical trials (2005)search PubMed for exenatide type 2 diabetes
- Byetta / Bydureon prescribing information · FDA prescribing information (2012)available via DailyMed / accessdata.fda.gov
TrackPep slouží ke sledování záznamů. Zaznamenává, co zadáte, a nikdy nedoporučuje ani nevypočítává množství.